Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study-Reference-Cited by-同舟云学术

Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study

Published:2017-05-09 Issue:3 Volume:19 Page:e12694
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Monforte Victor¹²,Sintes Helena¹²,López-Gallo Cristina³,Delgado Maria⁴,Santos Francisco⁵,Zurbano Felipe⁶,Solé Amparo⁷,Gavaldá Joan⁸,Borro Jose Maria⁴,Redel-Montero Javier⁵,Cifrian Jose Manuel⁶,Pastor Amparo⁷,Román Antonio¹²,Ussetti Piedad²³

Affiliation:

1. Respiratory Department; Hospital Universitari Vall d'Hebron; Universitat Autònoma de Barcelona; Barcelona Spain

2. Ciber Enfermedades Respiratorias (CIBERES); Instituto de Salud Carlos III; Madrid Spain

3. Respiratory Department; Hospital Puerta de Hierro; Madrid Spain

4. Thoracic Surgery Department; Complexo Hospitalario Universitario A Coruña; A Coruña Spain

5. Respiratory Department; Hospital Reina Sofía; Córdoba Spain

6. Respiratory Department; Hospital Marqués de Valdecilla; Santander Spain

7. Respiratory Department; Hospital La Fe; Valencia Spain

8. Infectious Disease Department; Hospital Universitari Vall d'Hebrón; Barcelona Spain

Funder

Roche Pharma Spain

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tid.12694/fullpdf

Reference63 articles.

1. Lungs are a major organ site of cytomegalovirus latency and recurrence;Balthesen;J Virol,1993

2. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients;Torre-Cisneros;Enferm Infecc Microbiol Clin,2011

3. Infections in solid-organ transplant recipients;Patel;Clin Microbiol Rev,1997

4. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation;Cope;J Infect Dis,1997

5. Cytomegalovirus in solid organ transplant recipients;Humar;Am J Transplant,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review;Transplant Infectious Disease;2023-05-31

2. Influence of Cytomegalovirus on the Survival of Cytomegalovirus-Seropositive Lung Transplant;Transplantation Proceedings;2021-11

3. CMV-specific Cell-Mediated Immunity Predicts High level of CMV Replication after Prophylaxis withdrawal in Lung Transplant Recipients;The Journal of Infectious Diseases;2020-11-27

4. Extending cytomegalovirus prophylaxis in high‐risk (D+/R−) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study;Transplant Infectious Disease;2020-03-27

5. Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era;Current Pulmonology Reports;2020-02-22